Expert Committee: FDA Should Allow Mitochondrial Replacement Trials Under Certain Conditions image

Regulatory Affairs, February 3, 2016
Zachary Brennan, quoting I. Glenn Cohen (Faculty Director)

Links

Read the Full Article

From the article:

Glenn Cohen, faculty director of the Petrie-Flom Center for Health Law Policy, Biotechnology and Bioethics at Harvard Law School, wrote on the center’s blog Wednesday: “The big headline is they have recommended FDA largely move toward allowing [MRT] to go forward under a regulatory pathway with restrictions, the most important of which is the transfer only of male embryos (to avoid germ-line issues)."

fda health law policy i. glenn cohen regulation reproductive rights